{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:10:00Z","timestamp":1775599800754,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>A growing list of therapies available for patients with multiple myeloma (MM) results in deep response rates, but eventually almost all patients relapse. Allogeneic hematopoietic cell transplantation (allo\u2010SCT) is a familiar approach for MM, but responses are often short and side effects burdensome. Simultaneously, allo\u2010SCT provides a unique platform on which novel immune therapies can be employed to improve clinical outcomes. Our work describes the characteristics and outcomes of 128 refractory myeloma patients who underwent allo\u2010SCT at five German centers between 2010 and 2021. The median number of therapies before the transplant was 6. With a median follow\u2010up of 6, 4\u2009years, the median progression\u2010free survival and overall survival were 7 and 19\u2009months, respectively. NRM was 28% after 6\u2009years. OS and PFS were 61% and 45% at 1\u2009year, 49% and 34% at 2\u2009years, and 38% and 25% at 6\u2009years. Achieving a CR before transplant was the single most significant variable before transplant. Allo\u2010SCT yet remains an option for fit patient's refractory to all other treatments available. It is potentially curative for a subset of patients. Finding the characteristics of patients with durable remissions is key to sparing unnecessary toxicity for those unlikely to benefit.<\/jats:p>","DOI":"10.1111\/ejh.14346","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T12:37:25Z","timestamp":1731501445000},"page":"423-428","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma\u2014A Retrospective Multicenter Analysis"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3588-6376","authenticated-orcid":false,"given":"T.","family":"Richardson","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine Medical Faculty and University Hospital of Cologne, University of Cologne  K\u00f6ln Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kobbe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University D\u00fcsseldorf  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fenk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University D\u00fcsseldorf  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"University Duisburg\u2010Essen, University Hospital Essen, Stem Cell Transplant  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Crysandt","sequence":"additional","affiliation":[{"name":"University Hospital Aachen, Medical Clinic IV, Stem Cell Transplantation  Aachen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Neuerburg","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn  Bonn Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD)  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias A.W.","family":"Holderried","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn  Bonn Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD)  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Sch\u00fctte","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Medical Faculty and University Hospital of Cologne, University of Cologne  K\u00f6ln Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"G\u00f6del","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Medical Faculty and University Hospital of Cologne, University of Cologne  K\u00f6ln Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hallek","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Medical Faculty and University Hospital of Cologne, University of Cologne  K\u00f6ln Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Scheid","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Medical Faculty and University Hospital of Cologne, University of Cologne  K\u00f6ln Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Holtick","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Medical Faculty and University Hospital of Cologne, University of Cologne  K\u00f6ln Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1312"},{"issue":"2","key":"e_1_2_9_4_1","first-page":"188","article-title":"Allogeneic Bone Marrow Transplantation in Multiple Myeloma European Group for Bone Marrow Transplantation","volume":"47","author":"Gahrton G.","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-337329"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07984.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-167379"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-469452"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.101"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200881"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065464"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7312"},{"issue":"5","key":"e_1_2_9_15_1","first-page":"1469","article-title":"Autologous\u2010Allogeneic Versus Autologous Tandem Stem Cell Transplantation and Maintenance Therapy With Thalidomide for Multiple Myeloma Patients Under 60\u2009Years of Age: A Prospective, Phase II Study","volume":"109","author":"Kr\u00f6ger N.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.10.008"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.43.43"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.025"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.08.004"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.024"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T03:02:01Z","timestamp":1739242921000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/ejh.14346"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14346","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"2024-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}